findmyKOL
Clinical trialNCT06046248RecruitingPhase 2Interventional

Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease

SponsorNorthside Hospital, Inc.Enrollment25Chronic Graft Versus Host Disease
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is an open-label, Phase 2 study designed to evaluate the safety and efficacy of belumosudil and rituximab as primary treatment of cGVHD.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Northside Hospital

    Atlanta, Georgia, United States

    Asad Bashey, MDH. Kent Holland, MDLawrence E Morris, MDLizamarie Bachier-Rodriguez, MDMelhem Solh, MDScott Solomon, MD →
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

BelumosudilRituximab
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
29 Jan 2024
Primary completion
31 Dec 2026
Completion
31 Dec 2027
Last update posted
20 Apr 2026
Registered enrollment
25
Registry id
NCT06046248
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.